Name,Category,Begin Date,End Date,Note
Initial Mammogram Abnormality,Milestones,2023-01-15,,Routine screening detected mass
Core Needle Biopsy,Biomarker Assess,2023-01-22,,Stage IIA confirmed
ER/PR/HER2 Testing,Biomarker Assess,2023-01-25,,Triple negative confirmed
PD-L1 Testing,Biomarker Assess,2023-01-25,,CPS score 15 - positive
BRCA Genetic Testing,Biomarker Assess,2023-02-01,,BRCA1 mutation detected
Port Placement,Milestones,2023-02-10,,
AC Chemo Cycles 1-4,Line 1 treatment,2023-02-15,2023-04-10,Doxorubicin/Cyclophosphamide every 2 weeks
Keytruda Cycles 1-4,Line 1 treatment,2023-02-15,2023-04-10,Pembrolizumab with AC
Taxol Cycles 1-12,Line 1 treatment,2023-04-17,2023-07-03,Weekly paclitaxel
Keytruda Cycles 5-8,Line 1 treatment,2023-04-17,2023-07-03,Pembrolizumab continued
Pre-surgical MRI,Biomarker Assess,2023-07-10,,Complete radiologic response
Lumpectomy with SLNB,Milestones,2023-07-20,,Pathologic complete response - pCR
Radiation Therapy,Line 1 treatment,2023-08-21,2023-10-02,30 fractions whole breast
Adjuvant Keytruda,Line 1 treatment,2023-10-09,2024-04-15,Pembrolizumab maintenance 9 cycles
Olaparib Started,Line 1 treatment,2023-10-09,2024-10-09,PARP inhibitor for BRCA1 - 1 year
6-Month Follow-up Clear,Milestones,2024-01-20,,No evidence of disease
12-Month Follow-up Clear,Milestones,2024-07-20,,NED continued
